April 24, 2019 | Michael Easterling and Samantha Bonar
City of Hope’s bone marrow transplant program recently performed the procedure on its 15,000th patient, a remarkable milestone considering that the initiative started with just two physicians, three beds and guarded expectations in 1976.
City of Hope awarded $7.5M to develop treatment for rare cancer
April 3, 2019 | Zen Vuong
City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.
City of Hope earns third prestigious Lymphoma SPORE Grant from NCI
February 26, 2019 | Letisia Marquez
City of Hope has earned its third Lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute, which provides $12.5 million for research.
Lucy’s Story: Immunotherapy Trial Gives Lymphoma Patient New Hope
July 19, 2018 | Dory Benford
After many complications, City of Hope lymphoma patient Lucy found renewed hope after an immunotherapy clinical trial.
Cheryl’s Story: CAR T Patient and Pioneer
April 30, 2018 | Letisia Marquez
Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.
City of Hope Physicians Announce New CAR T Breakthroughs at Annual ASH Meeting
December 14, 2017 | Letisia Marquez
New blood cancer breakthroughs – including several involving CAR T cell therapy – were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.
City of Hope doctor tackles two difficult-to-treat lymphomas
February 1, 2017 | Letisia Marquez
Alex F. Herrera, M.D., and a team of doctors examined how well patients whose double-hit and/or double-expressor lymphoma had recurred, or was resistant to initial treatment, fared after they had received high-dose chemotherapy and underwent an autologous stem cell transplantation.
Trial Results Point to Promising Treatments for Hodgkin Lymphoma Patients
January 9, 2017 | Abe Rosenberg
Everything changed when Hodgkin lymphoma patient Lowell Winer joined a phase 2 clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.